Clinical trials: Cardiovascular Outcomes
Heart Failure
The Darlington Retrospective Outpatient Study
Having heart failure means the heart is unable to pump blood around the body effectively. This reduces life expectancy and hinders normal daily activities.
- Trial name
- DROPSY (NCT01013883)
- Where
- United Kingdom
- Volunteers
- 509 people
- Sponsor
- County Durham and Darlington NHS Foundation Trust
Death, Congestive Heart Failure
Impact of Heart Failure Center Program on Cardiac Outcomes in Patients With Heart Failure
Congestive heart failure (CHF) is a major public health problem worldwide. CHF carries a devastating prognosis, which resembles that of some types of malignant cancer.
- Trial name
- NCT01416285
- Where
- Taiwan
- Volunteers
- 470 people
- Sponsor
- Chang Gung Memorial Hospital
Acute Coronary Syndrome
The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g.
- Trial name
- SOLID-TIMI 52 (NCT01000727)
- Testing
- Darapladib 160 mg, Standard Therapy
- Where
- 914 sites in United States, Argentina and 34 more
- Volunteers
- 13,026 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2, Acute Myocardial Infarction
Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
The primary objective was to demonstrate a difference between two insulin strategies, one targeting postprandial (PP) hyperglycemia and the other targeting fasting and interprandial hyperglycemia, on time until the first combined…
- Trial name
- IONM (NCT00191282)
- Testing
- Insulin lispro, Human insulin isophane suspension (NPH), Insulin glargine
- Where
- 17 sites in Canada, Croatia and 15 more
- Volunteers
- 1,116 people
- Sponsor
- Eli Lilly and Company
Diabetic Foot Ulcer
Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)
The primary objective of this study is to determine the outcomes of patients who receive a certain type of skin substitute called RestrataTM Wound Matrix (Restrata™).
- Trial name
- NCT03312595
- Testing
- Restrata TM Wound Matrix
- Where
- 5 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Acera Surgical, Inc.
Mobility Limitation, Physical Disability
Impact of More Frequent PT Services
The purpose of this study is to determine what amount of physical therapy is beneficial in the hospital setting after suffering a stroke. This study involves research.
- Conditions
- Mobility Limitation, Physical Disability, Stroke, Acute
- Trial name
- NCT04778475
- Testing
- Intensive therapy, Standard of care therapy
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Medical University of South Carolina
Ischemic Heart Disease
Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass
Ischemic heart disease is one of the most frequent diagnoses in the VA system. Moreover, 5,819 coronary artery bypass graft (CABG-only) procedures were performed in the VA in Fiscal Year (FY) 1999.
- Trial name
- ROOBY (NCT00032630)
- Testing
- Coronary artery bypass - on-pump, Coronary artery bypass - off-pump
- Where
- 17 sites in United States
- Volunteers
- 2,203 people
- Sponsor
- US Department of Veterans Affairs
Heart Failure
A Mobile Application to Promote Self-management and Improve Outcomes in Heart Failure
This study will investigate the effectiveness of two contextual just-in-time adaptive interventions (JITAIs) delivered via a mobile app for heart failure patients.
- Trial name
- NCT04755816
- Testing
- Sodium intervention, Clinical worsening intervention, Educational content
- Where
- 9 sites in United States
- Volunteers
- 62 people
- Sponsor
- University of Michigan
Coronary Artery Disease, Ischemic Heart Disease
The Randomized OPTIMAL-ACT Trial
The purpose of this study is to find the ideal range of the activated clotting time (ACT) during percutaneous coronary intervention (PCI) that is associated with lowering the rate of undesirable medical outcomes
- Conditions
- Coronary Artery Disease, Ischemic Heart Disease, Anticoagulant-induced Bleeding, Coronary Syndrome
- Trial name
- NCT03772613
- Testing
- Unfractionated heparin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Mayo Clinic
Patients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, Stroke
Registry on WATCHMAN Outcomes in Real-Life Utilization
The WATCHMAN LAA Closure Technology is designed to prevent embolization of thrombi that may form in the LAA, thereby preventing the occurrence of ischemic stroke and systemic thromboembolism.
- Trial name
- EWOLUTION (NCT01972282)
- Testing
- WATCHMAN Left Atrial Appendage Closure
- Where
- 47 sites in Belgium, France and 11 more
- Volunteers
- 1,025 people
- Sponsor
- Boston Scientific Corporation
Atrial Fibrillation, Bleeding
HEAL-LAA Clinical Trial
The primary objective of this study is to collect real-world data on WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device in patients with non-valvular atrial fibrillation.
- Conditions
- Atrial Fibrillation, Bleeding, Stroke
- Trial name
- HEAL-LAA (NCT05809596)
- Testing
- WATCHMAN FLX Pro LAAC Device
- Where
- 45 sites in United States
- Volunteers
- 949 people
- Sponsor
- Boston Scientific Corporation
Type 2 Diabetes, Cardiovascular Disease
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
The purpose of this study is to demonstrate no excess risk of cardiovascular (CV) composite events exists following long term treatment with TAK-875 compared with placebo.
- Trial name
- NCT01609582
- Testing
- TAK-875
- Where
- 584 sites in United States, Argentina and 30 more
- Volunteers
- 3,207 people
- Sponsor
- Takeda
Intracerebral Hemorrhage, Stroke
The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial
The purpose of this academic lead study is to determine if a treatment strategy of early intensive blood pressure (BP) lowering compared to conservative BP lowering policy in patients with elevated blood pressure within 6 hours…
- Conditions
- Intracerebral Hemorrhage, Stroke, Hypertension
- Trial name
- INTERACT2 (NCT00716079)
- Testing
- Blood pressure management policies
- Where
- 62 sites in United States, Argentina and 17 more
- Volunteers
- 2,839 people
- Sponsor
- The George Institute
Coronary Artery Disease, Myocardial Infarction
Colchicine Cardiovascular Outcomes Trial (COLCOT)
The study evaluates whether long-term treatment with colchicine reduces rates of cardiovascular events in patients after myocardial infarction.
- Trial name
- COLCOT (NCT02551094)
- Testing
- colchicine
- Where
- Canada
- Volunteers
- 4,745 people
- Sponsor
- Montreal Heart Institute
Pre-Eclampsia, Pre-Term
Vascular Inflammation and Anti-inflammatory Supplements After Adverse Pregnancy Outcomes
Women who had an adverse pregnancy outcome (APO), such as preeclampsia, preterm birth, or gestational diabetes, have a higher risk for heart disease.
- Conditions
- Pre-Eclampsia, Pre-Term, Intrauterine Growth Restriction, Hypertension in Pregnancy
- Trial name
- VIA (NCT04633551)
- Testing
- Anti-inflammatory supplement
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of South Carolina
Diabetes, Hypertension
Pharmacy Home Adherence Reporting and Monitoring Outcomes Study
This study is a pilot test of an intervention that delivers timely diagnostic information about medication nonadherence to doctors, and then offers the services of clinical pharmacists to treat these nonadherence problems.
- Conditions
- Diabetes, Hypertension, Hypercholesterolemia
- Trial name
- PHARxMOS (NCT02306122)
- Testing
- Pharmacist calls patient unless physician cancels call, Patient nonadherence information sent to physician, Pharmacist calls patient if physician requests call
- Where
- United States
- Volunteers
- 2,697 people
- Sponsor
- Brown University
Cardiovascular Diseases, Myocardial Infarction
Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coordination
This pragmatic clinical trial embedded in an accountable care organization will determine the comparative effectiveness of two approaches for assigning care coordinators to older adults at risk for cardiovascular outcomes.
- Conditions
- Cardiovascular Diseases, Myocardial Infarction, Atrial Fibrillation, Diabetes Mellitus
- Trial name
- NCT05820295
- Testing
- Care coordination delivered based on perceived need, Care coordination delivered based on usual care (e.g. discharge from hospital)
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Weill Medical College of Cornell University
Atherosclerotic Cardiovascular Disease
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
Primary Objective: To compare the effect of alirocumab with placebo on the occurrence of cardiovascular (CV) events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and…
- Trial name
- NCT01663402
- Testing
- Alirocumab, LMT
- Where
- 1,388 sites in United States, Argentina and 55 more
- Volunteers
- 18,924 people
- Sponsor
- Sanofi
Cardiovascular Disease, Cancer
COcoa Supplement and Multivitamin Outcomes Study
The purpose of this study is to determine whether taking daily, dietary supplements of cocoa extract (containing cocoa flavanols and theobromine from the cocoa bean) and/or a standard multivitamin reduces the risk of developing…
- Trial name
- COSMOS (NCT02422745)
- Testing
- Cocoa extract, Multivitamin
- Where
- 2 sites in United States
- Volunteers
- 21,442 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Complication of Renal Dialysis, End Stage Renal Disease
A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
The primary study objective is to evaluate the benefit of the Sirolimus eluting Collagen implant (SeCI; Sirogen), a single dose prophylactic treatment delivered intraoperatively at the time of surgical creation of an…
- Conditions
- Complication of Renal Dialysis, End Stage Renal Disease, End Stage Kidney Disease, ESRD
- Trial name
- ACCESS2 (NCT05425056)
- Testing
- Sirolimus
- Where
- 22 sites in United States, United Kingdom
- Volunteers
- 136 people
- Sponsor
- Vascular Therapies, Inc.